PAVmed subsidiary Veris Health launches cancer care platform at OSU center

NEW YORK - PAVmed Inc. (NASDAQ:PAVM), a medical technology company with a current market capitalization of $9.56 million and shares trading near $0.45, announced Tuesday that its majority-owned digital health subsidiary Veris Health has begun the commercial phase of its strategic partnership with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). According to InvestingPro data, the company’s stock has declined over 62% in the past year, highlighting the importance of this commercial milestone.

The partnership will deploy the Veris Cancer Care Platform across the cancer center to enhance personalized care for patients undergoing systemic cancer therapy. The platform integrates remote physiological monitoring, symptom reporting, telehealth capabilities, and electronic health record integration. InvestingPro analysis reveals several key challenges for PAVmed, including rapid cash burn and anticipated sales decline in the current year - just two of multiple insights available to subscribers.

"We have expanded our strategic partnership from a pilot phase to a full engagement across The James including launching a clinical registry on patients enrolled on the platform," said David Cohn, M.D., M.B.A., Chief Operating Officer and Chief Medical Officer at The James Cancer Hospital.

Patients enrolled in the program receive a VerisBox containing connected healthcare devices that transmit physiological data to a cloud-based clinician portal. A companion smartphone app allows patients to report symptoms and health parameters while enabling caregivers and family members to follow the treatment journey.

The OSUCCC - James is an NCI-Designated Comprehensive Cancer Center and one of the largest academic cancer centers in the nation. The implementation represents a significant expansion of Veris Health’s commercial footprint.

According to the press release statement, Veris is also developing an implantable physiological monitor designed to be placed alongside a vascular access port, which would provide remote data collection independent of patient compliance.

PAVmed operates in the medical device, diagnostics, and digital health sectors, with subsidiaries including Veris Health and Lucid Diagnostics. With an InvestingPro Financial Health Score of 2.36 (rated as ’FAIR’), investors seeking deeper insights into PAVmed’s financial position can access comprehensive analysis through InvestingPro’s detailed research reports, which provide extensive coverage of over 1,400 US stocks.

In other recent news, Lucid Diagnostics reported a significant increase in revenue for the second quarter of 2025, largely attributed to the strong performance of its EsoGuard esophageal precancer test. The company has also laid out strategic plans to enhance its position within the Medicare market, indicating a focus on expanding its reach and services. In addition to these financial developments, Lucid Diagnostics announced the appointment of John R. Palumbo to its Board of Directors, effective September 22, 2025. Palumbo brings a wealth of experience from his 40-year career in healthcare leadership, having previously served as Executive Chairman of ValueHealth. His experience spans early-stage ventures, growth companies, and Fortune 100 corporations, which may provide valuable insights for Lucid Diagnostics. These recent developments highlight the company’s ongoing efforts to strengthen its market position and leadership team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.